(Q39461774)

12 September 2017

Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study (English)

1 reference

12 September 2017

1 reference

4

Michael Saag

1 reference

12 September 2017

11

Jayvant Heera

1 reference

12 September 2017

Juan Sierra-Madero

1

1 reference

12 September 2017

Giovanni Di Perri

2

1 reference

12 September 2017

Robin Wood

3

1 reference

12 September 2017

Ian Frank

5

1 reference

12 September 2017

Charles Craig

6

1 reference

12 September 2017

Robert Burnside

7

1 reference

12 September 2017

Jennifer McCracken

8

1 reference

12 September 2017

Dennis Pontani

9

1 reference

12 September 2017

James Goodrich

10

1 reference

12 September 2017

Howard Mayer

12

1 reference

12 September 2017

1 May 2010

1 reference

12 September 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

HIV Clinical Trials

1 reference

12 September 2017

11

1 reference

12 September 2017

3

1 reference

12 September 2017

125-132

1 reference

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

12 September 2017

1 reference

https://api.crossref.org/works/10.1310%2FHCT1103-125

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1103-125

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1103-125

Class-sparing regimens for initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1103-125

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1103-125

Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1103-125

CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1103-125

Should the CD4 threshold for starting ART be raised?

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1103-125

21 January 2018

Identifiers

DOI

10.1310/HCT1103-125

1 reference

release_sauvtlytqrbjzgwigi2ype7q3e

12 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sauvtlytqrbjzgwigi2ype7q3e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference